Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 27, 2022

SELL
$8.12 - $16.9 $70,619 - $146,979
-8,697 Closed
0 $0
Q4 2021

Jan 31, 2022

SELL
$15.91 - $21.88 $55,175 - $75,879
-3,468 Reduced 28.51%
8,697 $140,000
Q3 2021

Nov 03, 2021

BUY
$19.74 - $28.7 $240,137 - $349,135
12,165 New
12,165 $255,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Dupont Capital Management Corp Portfolio

Follow Dupont Capital Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Dupont Capital Management Corp with notifications on news.